AFT Pharmaceuticals Limited (ASX:AFP)
Australia
· Delayed Price · Currency is AUD | Market Cap | 305.42M |
| Revenue (ttm) | 207.12M |
| Net Income (ttm) | 15.30M |
| Shares Out | n/a |
| EPS (ttm) | 0.14 |
| PE Ratio | 19.97 |
| Forward PE | 20.58 |
| Dividend | 0.02 (0.53%) |
| Ex-Dividend Date | Jun 18, 2025 |
| Volume | 60 |
| Average Volume | 2,040 |
| Open | 3.190 |
| Previous Close | 3.190 |
| Day's Range | 3.190 - 3.190 |
| 52-Week Range | 2.200 - 3.370 |
| Beta | 0.38 |
| RSI | 62.73 |
| Earnings Date | May 21, 2026 |
About AFT Pharmaceuticals
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta... [Read more]
Financial Performance
In fiscal year 2025, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.
Financial numbers in NZDNews
AFT Pharmaceuticals Ltd (ASX:AFP) Half Year 2026 Earnings Call Highlights: Strong Sales Growth ...
AFT Pharmaceuticals Ltd (ASX:AFP) Half Year 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Expansion
Half Year 2026 AFT Pharmaceuticals Ltd Earnings Call Transcript
Half Year 2026 AFT Pharmaceuticals Ltd Earnings Call Transcript
AFT Pharmaceuticals Earnings Call Transcript: H1 2026
Sales grew 33% year-over-year to nearly NZD 115 million, with strong gains in Australia, Asia, and international markets. Operating profit rebounded to NZD 4.7 million, and guidance for EBIT and revenue was maintained despite higher R&D and ERP costs.
AFT Pharmaceuticals Transcript: AGM 2025
The meeting highlighted record revenue, robust Australasian performance, and ambitious global expansion plans. An increased dividend was announced, and the board emphasized ongoing R&D investment and governance. Shareholders approved all resolutions, including director appointments.
AFT Pharmaceuticals Earnings Call Transcript: H2 2025
Sales reached NZD 208 million, with strong growth in Australia and New Zealand and ongoing global expansion. Operating profit was impacted by lower licensing income and continued investment, but net debt and dividends improved. FY 2026 EBIT guidance is NZD 20–24 million.
AFT Pharmaceuticals Earnings Call Transcript: H1 2025
First-half FY25 revenue grew 4% to NZD 86.7 million, with strong gains in Australia and New Zealand offset by one-off events in Asia and international markets. A strong second-half recovery is expected, with full-year EBITDA guidance of NZD 15–20 million and a sales target of NZD 300 million by FY27.
AFT Pharmaceuticals Transcript: AGM 2024
The meeting highlighted strong revenue and profit growth, global expansion, and a robust product pipeline, with a focus on long-term R&D investment and sustainability. Shareholders approved all resolutions and discussed share price concerns, governance, and future strategic plans.